So on that note, Ypsomed Holding (VTX:YPSN) looks quite promising in regards to its trends of return on capital. If you haven't worked with ROCE before, it measures the 'return' (pre-tax profit ...
So on that note, Ypsomed Holding (VTX:YPSN) looks quite promising in regards to its trends of return on capital. If you haven't worked with ROCE before, it measures the 'return' (pre-tax profit) a ...
0.13 = CHF87m ÷ (CHF1.2b - CHF513m) (Based on the trailing twelve months to September 2024). So, Ypsomed Holding has an ROCE of 13%. That's a pretty standard return and it's in line with the industry ...
Trump Names Scott Bessent as His Pick for Treasury Secretary The billionaire hedge fund manager would be responsible for steering President-elect Trump’s unconventional economic agenda. Mr ...
Ozempic, Wegovy and Mounjaro are often the most popular weight loss drugs. While these medications help people lose weight, they have undesirable side effects. Now, scientists at the University of ...
GLP-1 medications are breakthroughs for weight loss, diabetes, and more. Pharma companies are clamoring to produce pills or longer-lasting drugs with faster effects. Novo Nordisk, Eli Lilly ...
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...
Novo Nordisk’s median P/E ratio has been 26.40 from 2010 to the present. The following price predictions are based on a 25 P/E. In the subsequent 5 years to follow, Novo Nordisk’s newest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback